AnalystBook Research · Company Intelligence

Harmony Biosciences Holdings, Inc.

HRMYNasdaq

Built from Harmony Biosciences Holdings, Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data

Revenue increased 21.5% to $868.5M, while Net income increased 9.1% to $158.7M.

The read at a glance✓ Audited against SEC data
  • Scale — FY2025 revenue $868.5MOK
  • Profitability — Net income $158.7MOK
  • Cash generation — Free cash flow $347.9MOK
  • Accounting — Formula-grey distress score · no manipulation flag · earnings quality safeNote
  • Insiders — 0 buys; 6 sells in 365 daysNote
  • Capital — share repurchases were $100.0MNote

Business

Harmony Biosciences Holdings, Inc.: Management's Discussion and Analysis of Financial Condition and Results of Operations." Moreover, we operate in an evolving environment.

Where the revenue comes from

Fiscal 2025, as Harmony Biosciences Holdings, Inc. reports it. History and quarterly detail are in the app.

  • Rare Neurological Diseases$868.5M

Leadership changes

From Harmony Biosciences Holdings, Inc.'s own filings, the day they're filed.

  • Glenn Reicin · Chief Financial Officer · appointmenteff. 2026-04-14
  • Sandip Kapadia · Chief Financial Officer · departureeff. 2026-04-14
  • Peter Anastasiou · Chief Operating Officer · departureeff. 2026-04-02

Latest filings

  • 10-Q · Quarterly report2026-08-04
  • 8-K · Company announcement2026-08-04
  • 8-K · Company announcement2026-07-16
  • 8-K · Company announcement2026-05-14
  • 10-Q · Quarterly report2026-05-07
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Harmony Biosciences Holdings, Inc., every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

See the full HRMY record — start free

14-day free trial, no credit card. For research purposes only; not investment advice.